Patents by Inventor Christopher Teleha

Christopher Teleha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070225282
    Abstract: The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.
    Type: Application
    Filed: March 13, 2007
    Publication date: September 27, 2007
    Inventors: Mark Player, Tianbao Lu, Huaping Hu, Xizhen Zhu, Christopher Teleha, Kevin Kreutter
  • Patent number: 7262210
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: August 28, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kevin Kreutter, Tianbao Lu, Yu Kai Lee, Christopher Teleha, Mark Player, Xizhen Zhu
  • Publication number: 20060241148
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
    Type: Application
    Filed: March 21, 2006
    Publication date: October 26, 2006
    Inventors: Kevin Kreutter, Tianbao Lu, Yu Lee, Christopher Teleha, Mark Player, Xizhen Zhu
  • Publication number: 20040198787
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: 1
    Type: Application
    Filed: April 15, 2004
    Publication date: October 7, 2004
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Lucius T. Rossano, Christopher A. Teleha, Jiacheng Zhou, Thomas E. Smyser
  • Patent number: 6747158
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: from its corresponding 3-cyano-4-fluorophenyl-pyrazole and intermediates useful therein.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: June 8, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Lucius T. Rossano, Christopher A. Teleha, Jiacheng Zhou, Thomas E. Smyser
  • Patent number: 6667332
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: from its corresponding 3-cyano-4-fluorophenyl-pyrazole and intermediates useful therein.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: December 23, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Christopher A. Teleha, Jia C. Zhou, Thomas E. Smyser
  • Publication number: 20030212117
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: 1
    Type: Application
    Filed: May 7, 2003
    Publication date: November 13, 2003
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Lucius T. Rossano, Christopher A. Teleha, Jiacheng Zhou, Thomas E. Smyser
  • Patent number: 6417394
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: July 9, 2002
    Assignee: Bristol Myers Squibb Pharma Company
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy
  • Publication number: 20020061917
    Abstract: The present invention relates to the process for the preparation of the compound of Formula I: 1
    Type: Application
    Filed: September 21, 2001
    Publication date: May 23, 2002
    Inventors: Hui-Yin Li, Luigi Anzalone, Fuqiang Jin, David J. Meloni, Jung-Hui Sun, Christopher A. Teleha, Jia C. Zhou, Thomas E. Smyser
  • Publication number: 20020004496
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 10, 2002
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy
  • Patent number: 5955475
    Abstract: Solid dispersions of poorly soluble drugs are disclosed which are prepared using a solvent or fusion process. Such dispersions are manufactured with the free base of the drug, specifically paroxetine free base, an oil, allowing for a low temperature for the fusion process, decreased organic solvent volumes for the solvent process and the formation of a paroxetine salt during the solid dispersion manufacture process.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: September 21, 1999
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Philip J. Krape, Sou-Chan Chang, William A. Hein, II, Christopher A. Teleha
  • Patent number: 5597916
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful as chemical intermediates and as pharmacological agents in the treatment of diseases of man, such as in Alzheimer's Disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: January 28, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventor: Christopher A. Teleha
  • Patent number: 5594001
    Abstract: Compounds of Formula (I) have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man where subnormal levels of this neurochemical are found, such as in Alzheimer's disease, and other conditions involving learning and cognition.
    Type: Grant
    Filed: March 28, 1994
    Date of Patent: January 14, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Christopher A. Teleha, Wendell W. Wilkerson, Richard A. Earl
  • Patent number: 5532249
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man, such as in Alzheimer's disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.The compounds of this invention can be described as shown in Formula I ##STR1## where Q is ##STR2## R.sup.1 is 4-,3-, or 2-pyridyl, pyrimidyl, pyrazinyl, or fluoro-4-pyridyl; R.sup.2 and R.sup.3 are independently H, F, Cl, Br, NO.sub.2, OH, --R.sup.4, --O--R.sup.4, --CO.sub.2 R.sup.4, --COR.sup.4, --CONH.sub.2, --CONHR.sup.4, --CONR.sup.4 R.sup.4', --S(O).sub.m2 -- R.sup.4, NH.sub.2, CF.sub.3, NHR.sup.4, NR.sup.4 R.sup.4' ;R.sup.4 and R.sup.4' are independently H, alkyl of 1 to 4 carbons, CH.sub.2 Phe-W or Phe-W;and hydrates and physiologically suitable salts thereof.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: July 2, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Wendell W. Wilkerson, Christopher A. Teleha
  • Patent number: 5519132
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful as chemical intermediates and as pharmacological agents in the treatment of diseases of man, such as in Alzheimer's Disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: May 21, 1996
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventor: Christopher A. Teleha
  • Patent number: 5428035
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful as chemical intermediates and as pharmacological agents in the treatment of diseases of man, such as in Alzheimer's Disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: June 27, 1995
    Assignee: The Dupont Merck Pharmaceutical Company
    Inventor: Christopher A. Teleha
  • Patent number: 5308851
    Abstract: Bispyridyl-containing heterocycles, or pharmaceutically acceptable salts thereof, are useful in treating neurological disorders in mammals. The compounds have efficacy over a broad dosage ranges as measured in both neurotransmitter release assay and by hypoxia induced cognition deficit.
    Type: Grant
    Filed: June 3, 1993
    Date of Patent: May 3, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Christopher A. Teleha, Matthew E. Voss
  • Patent number: 5296478
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetlcholine, and thus may be useful as chemical intermediates and as pharmacological agents in the treatment of diseases of man, such as in Alzheimer's Disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.
    Type: Grant
    Filed: October 7, 1992
    Date of Patent: March 22, 1994
    Assignee: The DuPont Merck Pharmaceutical Co.
    Inventor: Christopher A. Teleha